tbuckley/cabot-search huggingface dataset:
STEM-17. LOW GRADE ASTROCYTOMA MUTATIONS COOPERATE TO DISRUPT SOX2 GENOMIC ARCHITECTURE AND BLOCK DIFFERENTIATION VIA PREVIOUSLY UNIDENTIFIED ENHANCER ELEMENTS
Authors: Devin Bready, Aram Modrek, Adler Guerrera, Joshua Frenster, Jane Skok, Dimitris Placantonakis
Journal: Neuro-Oncology (2019)

Abstract Neomorphic mutations in isocitrate dehydrogenase I (IDH1) result in the formation of the oncometabolite 2-hydroxyglutarate (2HG) in a significant subset of gliomas and other tumors including acute myeloid leukemias. Preclinical evidence suggests that gliomas harboring IDH1 mutations undergo widespread, long-lasting modifications to the epigenome that persist following inhibition of 2HG production. However, the exact mechanism underlying gliomagenesis remains unclear. To address difficulties in growing these tumors in culture, our group generated a model of low-grade astrocytoma in human neural stem cells (NSCs). This model, referred to as 3-Hit NSCs, suggested a block in differentiation potential underlies gliomagenesis at the cellular level. This block is rescued by restoration of expression of the transcription factor (sex determining region Y)-box 2 (SOX2), which is transcriptionally downregulated during IDH mutant gliomagenesis. We believe that these changes occur secondary to profound alterations in 3-dimensional chromatin organization around the SOX2 genomic locus. Our preliminary data suggest SOX2 expression in control NSCs depends on 3-dimensional association of its promoter to an uncharacterized, distal enhancer located 600 kb telomeric to the SOX2 gene. We believe this association is disrupted in 3-Hit NSCs due to eviction of chromatin organizer CTCF from its motifs in the SOX2 topologically associating domain (TAD). To test this hypothesis, we used CRISPR-Cas9 technology to excise CTCF motifs immediately upstream of the SOX2 promoter and in the region of the putative enhancer in control NSCs. Excision of such motifs significantly reduced SOX2 mRNA levels and impaired growth of control NSCs. We are currently working on characterizing this novel SOX2-enhancer interaction in native stem cells, as well as tumors that depend on SOX2 expression. This works aims to elucidate the core epigenetic mechanisms underlying IDH mutant gliomagenesis. Our findings will be used to improve therapy in IDH-mutant glioma.
Optical biopsy in real time by endocytoscopy: a case of juvenile polyp
Authors: Kaizo Kagemoto, Yutaka Saito, Yasuhiko Mizuguchi, Taku Sakamoto, Hirokazu Taniguchi, Shigeki Sekine, Tetsuji Takayama
Journal: Endoscopy (2019)

Endocytoscopy allows ultra-high magnification, thereby enabling observation of structural and cellular atypia [1] [2]. Additionally, endocytoscopy has been reported to have high diagnostic performance in differentiating neoplastic from nonneoplastic colorectal polyps, and can provide an alternative histological diagnosis to standard biopsy [3] [4].
EXTH-34. IN VITRO TUMOR TREATING FIELDS (TTFIELDS) APPLIED PRIOR TO RADIATION ENHANCES THE RESPONSE TO RADIATION IN PATIENT-DERIVED GLIOBLASTOMA CELL LINES
Authors: Sharon Michelhaugh, Sandeep Mittal
Journal: Neuro-Oncology (2019)

Abstract Tumor treating fields are FDA-approved for treatment of newly-diagnosed and recurrent glioblastoma. Adding TTFields therapy to standard-of-care extended progression-free survival and overall survival in newly-diagnosed glioblastoma patients. In this study, cell lines generated from newly-diagnosed glioblastoma patients were treated in vitro with TTFields prior to irradiation to determine if the response to radiation would be altered. This study was approved by the WSU Institutional Review Board and written consent obtained from the patients. Single-cell suspensions generated from tumor tissues obtained from newly-diagnosed patients were cultured in DMEM/F12 media with 10% fetal bovine serum and gentamicin. Prior to TTFields initiation, cells were plated on plastic coverslips (5×104cells/coverslip) and incubated overnight. Then, TTFields were applied at 200 kHz with a field intensity of ~1.6 V/cm for 3 days. After TTFields application, cells were irradiated with 2, 4, or 6 Gy, or were untreated. After radiation delivery, cells were harvested and replated in a clonogenic assay. From each group, 3 coverslips were each replated in triplicate. After 3 days (3 doubling times), cells were stained with crystal violet and plates were scanned to determine cell counts. Treatment groups were compared to their control group with t-test. For both patient-derived GBM cell lines tested, TTFields prior to radiation decreased the number of crystal violet-stained cells in the clonogenic assay plates. In cell line 15–037, pretreatment with TTFields decreased cell counts by 16, 29, and 56% after 2, 4, or 6 Gy radiation, respectively, compared to the control cells with no TTFields pretreatment (p&lt; 0.05). The response in 14-015S cells was less radiation dose-dependent, with the decrease in cell counts ranging from 33–47% control across the radiation doses (p&lt; 0.05). These data suggest that the use of TTFields therapy prior to radiotherapy may enhance the response to radiotherapy in GBM patients.
Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications
Authors: Vera Adema, Laura Palomo, Cassandra M Kerr, Wencke Walter, Bartlomiej Przychodzen, Stephan Hutter, Thomas Laframboise, María Díez-Campelo, Mar Mallo, Aziz Nazha, Blanca Xicoy, Manja Meggendorfer, Hetty E. Carraway, Claudia Haferlach, Mikkael A. Sekeres, Valeria Visconte, Torsten Haferlach, Francesc Sole, Jaroslaw P. Maciejewski
Journal: Blood (2019)
SCIDOT-22. INTRACEREBROVENTRICULAR DELIVERY OF TUMOR-HOMING CYTOTOXIC HUMAN INDUCED NEURAL STEM CELLS FOR TREATMENT OF BRAIN METASTASES
Authors: Wulin Jiang, Alison Mercer-Smith, Juli Bago, Simon Khagi, Carey Anders, Shawn Hingtgen
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Non-small cell lung cancer (NSCLC) and breast cancer are the most common cancers that metastasize to the brain. New therapies are needed to target and eradicate metastases. We have developed genetically-engineered induced neural stem cells (hiNSCs) derived from human fibroblasts that selectively home to tumors and release the cytotoxic protein TRAIL. Building on these results, we explored the efficacy of hiNSC therapy delivered via intracerebroventricular (ICV) injections for the treatment of metastatic foci in the brain for the first time. METHODS We performed in vitro efficacy and migration assays in conjunction with in vivo studies to determine the migration, persistence, and efficacy of therapeutic hiNSCs against H460 NSCLC and triple-negative breast cancer MB231-Br tumors in the brain. Following the establishment of tumors in the brains of nude mice, hiNSCs were injected directly into the tumor or the ventricle contralateral to the tumor. The migration and persistence of hiNSCs were investigated by following the bioluminescence of the hiNSCs. The therapeutic efficacy of the hiNSCs was determined by following the bioluminescence of the tumor. RESULTS/ CONCLUSION Co-culture results demonstrated that hiNSC therapy reduced the viability of H460 and MB231-Br up to 75% and 99.8% respectively compared to non-treated controls. In vitro migration assays showed significant directional migration toward both lung and breast cancer cells within 4 days. ICV-administered hiNSC serial imaging shows that cells persisted for &gt;1 week in the brain. Fluorescent analysis of tissue sections showed that hiNSCs co-localized with lateral and contralateral tumors within 7 days. Using H460 and MB231-Br models, kinetic tracking of intracranial tumor volumes showed intratumoral or ICV-injected therapeutic hiNSCs suppressed the growth rate of brain tumors by 31-fold and 3-fold, respectively. This work demonstrates for the first time that we can effectively deliver personalized cytotoxic tumor-homing cells through the ventricles to target brain metastases.
Vaccination Against Poly-N-Acetylglucosamine Decreases Neutrophil Activation and Gvhd While Maintaining Microbial Diversity
Authors: Eileen Haring, Jan Hülsdünker, Oliver Thomas, Susanne Unger, Nicolás Núñez, Sonia Tugues, Sandra Duquesne, Colette Cywes-Bentley, Özlem Oyardi, Zhan Ghao, Susanne Kirschnek, Dr. Schmitt-Graeff, Oliver Pabst, Christian Koenecke, Justus Duyster, Petya Apostolova, Martin Blaser, Burkhard Becher, Gerald Pier, Georg Häcker, Robert Zeiser
Journal: Blood (2019)
The Economic and Health Utilization Cost of Clinically Significant Cytomegalovirus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Michelle K Yong, Shio Yen Tio, Jake Valentine, Joe Sasadeusz, Lynette C.Y. Chee, Ashish Bajel, David Ritchie, Monica Slavin
Journal: Blood (2019)
HOUT-06. SYSTEMIC METABOLIC BIOMARKERS OBTAINED FROM COMPUTED TOMOGRAPHY (CT)-BASED BODY COMPOSITION AND SERUM GLUCOSE PREDICT SEX-SPECIFIC SURVIVAL IN PATIENTS WITH GLIOBLASTOMA
Authors: Muhammad Naeem, Shama Jaswal, Amy Killeen, David Ballard, Norman Atagu, Samantha Lancia, Amber Salter, John Evans, Vincent Mellnick, Sonika Dahiya, Michael Chicoine, Joseph Ippolito
Journal: Neuro-Oncology (2019)

Abstract In many cancers including glioblastoma, males have higher incidence and mortality. Although the mechanisms underlying this phenomenon have yet to be elucidated, there are inherent sex differences in metabolism. Males not only have higher glucose metabolism relative to females, but males also have higher amounts of abdominal visceral fat, a well-known metabolic biomarker for poor cardiovascular and cancer outcomes that could contribute to enhanced tumorigenesis. Previously, we identified that in renal cell carcinoma, females with male-pattern visceral fat did significantly poorly compared to all other patients (PMID 29558292) and that in lower grade gliomas, tumor glycolysis specifically stratified males (PMID: 28768910). We hypothesized that in glioblastoma, visceral fat would selectively stratify females and serum glucose would selectively stratify males. We retrospectively analyzed abdominal/pelvic computed tomographic (CT) datasets for the normalized relative visceral fat area (rVFA) and random glucose measurements at diagnosis from 159 males and 105 females with glioblastoma. Females with rVFA &gt; 30.5% had significantly reduced median overall survival (OS) (11.6 months, n=63) vs females with rVFA &lt; 30.5% (20.9 months, n=42, p=0.006), that was close to the median rVFA of 32.7%. For males, the optimized rVFA threshold was higher than the median (43.6%); males with rVFA &gt; 58.9% had significantly reduced median OS (10.7 months, n=14) compared to males with rVFA &lt; 58.9% (20.5 months, n=145, p=0.02). However, after adjusting rVFA for age and tumor size, it was an independent predictor in females, but not in males. Conversely, there was a male-specific survival effect of glucose: males with prediabetic random serum glucose greater than 179.5 mg/dL had shorter OS (9.9 months vs 20.9 months; p=0.007), where no glucose level could stratify females. These data support the use of metabolism to predict sex-specific cancer outcomes and suggest that interventions that target metabolism can improve sex-specific outcomes in glioblastoma.
Coronary Functional Abnormalities in Patients With Angina and Nonobstructive Coronary Artery Disease
Authors: Akira Suda, Jun Takahashi, Kiyotaka Hao, Yoku Kikuchi, Tomohiko Shindo, Shohei Ikeda, Koichi Sato, Jun Sugisawa, Yasuharu Matsumoto, Satoshi Miyata, Yasuhiko Sakata, Hiroaki Shimokawa
Journal: Journal of the American College of Cardiology (2019)

Approximately one-half of patients undergoing diagnostic coronary angiography for angina have no significant coronary stenosis, in whom coronary functional abnormalities could be involved. This study examined the significance of coronary functional abnormalities in a comprehensive manner for both epicardial and microvascular coronary arteries in patients with angina and nonobstructive coronary artery disease (CAD). This study prospectively enrolled 187 consecutive patients (male/female 113/74, 63.2 ± 12.3 years), who underwent acetylcholine provocation test for coronary spasm and measurement of index of microcirculatory resistance (IMR) to evaluate coronary microvascular function, and followed them for a median of 893 days. Of all subjects, acetylcholine test identified 128 patients with vasospastic angina (VSA) (68%), and cardiac events occurred in 10 patients (5.3%) during the follow-up. Multivariable analysis revealed that IMR correlated with the incidence of cardiac events (hazard ratio: 1.05; 95% confidence interval: 1.02 to 1.09; p = 0.002) and receiver-operating characteristics (ROC) curve analysis identified IMR of 18.0 as the optimal cut-off value. Among the 4 groups based on the cut-off value of IMR and the presence of VSA, the Kaplan-Meier survival analysis showed a significantly worse prognosis in the group with high IMR (≥18.0) and VSA compared with other groups (log rank, p = 0.002). Importantly, intracoronary administration of fasudil, a Rho-kinase inhibitor, significantly ameliorated IMR in the VSA patients with increased IMR (p < 0.0001). These results indicate that in patients with angina and nonobstructive CAD, coexistence of epicardial coronary spasm and increased microvascular resistance is associated with worse prognosis, for which Rho-kinase activation may be involved.
Medical costs of sorafenib compared with sunitinib in treatment of patients &lt;65 years with renal cell carcinoma: A retrospective claims database analysis
Authors: D. Quinn, V. Barghout, E. Moyneur
Journal: Journal of Clinical Oncology (2009)

e17536 Background: Sorafenib (SR) and sunitinib (SU) are FDA approved (12/05 and 1/06, respectively) tyrosine kinase inhibitors for patients (pts) with advanced renal cell carcinoma (RCC). Little is known of their cost impact. We conducted this study to quantify overall direct costs (inpatient, outpatient, pharmacy) for each treatment in privately insured pts (&lt;65 y). Given differences between private and public insurer payment scales, pts ≥65 y were not included in this study but are the subject of a planned further analysis. Methods: A retrospective US claims-based study was conducted using data covering all US census regions for ≥18 million lives from MarketScan MedStat (1/02–12/07). Inclusion criteria were ≥2 RCC claims (ICD-9 189.0, 198.0), continuous health care coverage, &gt;180 days of coverage before RCC diagnosis. SR and SU pts were identified based on oral therapy after initial RCC-related claim (intent-to-treat). Observation period was from first drug-dispensing date until ≤12 mo or first of therapy switch, nephrectomy, disenrollment, or study end (12/31/07). Univariate and multivariate Tobit analyses were conducted; control factors included age, sex, region, plan type, comorbidity, prior Tx/procedures, and time since RCC Dx. Results: Of 10,462 RCC pts identified, 144 and 220 received initial therapy with SR and SU, respectively. In the 180 days before RCC diagnosis, total direct medical costs, baseline demographics, and comorbidities were similar between groups. The univariate incremental total monthly medical cost for SU was $2,049 (P&lt;.001) more than for SR, representing yearly costs for SU $24,588 more than for SR. Multivariate analyses for incremental total monthly costs for SU also remained significant at $1,399 (P&lt;.001). Conclusions: Retrospective analysis of this US claims database for RCC pts &lt;65 treated first with SR showed statistically significant lower total medical costs (particularly inpatient costs) than for pts treated first with SU. [Table: see text] [Table: see text]
Long Range Sequencing Shows Improved Resolution in the Detection of Beta Globin Cluster Variants
Authors: Aruna Rangan, Molly S. Hein, Tejaswi Koganti, William G. Jenkinson, Christopher A. Hilker, Joseph H. Blommel, Tavanna R. Porter, Jin Jen, Nicole Hoppman, Rong He, David S. Viswanatha, Ross Aleff, James D. Hoyer, Eric Wieben, Eric W. Klee, Benjamin R. Kipp, Jennifer L. Oliveira
Journal: Blood (2019)
Patient Repositioning Reveals a Malignant Pleura Effusion Initially Mistaken as a Bone Metastasis on 18FDG PET/CT
Authors: Julian Kirchner, Christopher C. Riedl, Gary A. Ulaner
Journal: Clinical Nuclear Medicine (2019)

A 70-year-old woman with breast cancer underwent F-FDG PET/CT for restaging. An FDG-avid focus corresponding to a rib on CT images was identified and interpreted as suggestive of an osseous metastasis. A PET/CT-guided biopsy was planned with the patient in prone position. Prone images demonstrated the FDG focus "moved" to the anterior chest and corresponding to pleural fluid. The diagnosis was altered from osseous metastases to pleural malignancy, and the bone biopsy was not performed. This case not only emphasizes the sensitivity of PET in the detection of malignancy, but also highlights the difficulty localizing small, mobile, FDG-avid foci.
ATIM-07. EFFICACY AND SAFETY OF NIVOLUMAB IN PATIENTS WITH FIRST RECURRENCE OF GLIOBLASTOMA: A MULTICENTER, OPEN-LABEL, NON-COMPARATIVE STUDY (ONO-4538-19)
Authors: Naoki Kagawa, Tomokazu Aoki, Kazuhiko Sugiyama, Toshihiko Wakabayashi, Yoshiki Arakawa, Shigeru Yamaguchi, Shota Tanaka, Ryo Nishikawa
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The anti-programmed cell death protein 1 (PD-1) immune checkpoint antibody, nivolumab, may be beneficial in patients with recurrent glioblastoma. OBJECTIVE This open-label, non-comparative study assessed the efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma. METHODS Patients with a first recurrence of histologically confirmed World Health Organization (WHO) Grade IV glioma, after treatment with temozolomide plus radiotherapy, received nivolumab 3 mg/kg every 2 weeks until confirmed disease progression based on Response Assessment in Neuro-Oncology (RANO) criteria or development of toxicity. The primary endpoint was 1-year overall survival rate (1y-OS) assessed using a Bayesian approach. The prespecified efficacy criteria were that the Bayesian posterior mean 1y-OS with nivolumab would be 49%, and the Bayesian posterior probability threshold for exceeding the 1y-OS of bevacizumab (34.5%) from the Japanese Phase II study (JO22506) would be 93%. RESULTS Of the 50 patients enrolled, 44 (93.5%) had recurrent malignant glioma (glioblastoma and gliosarcoma), 26 (59.1%) had measurable disease, and 4 (9.1%) received corticosteroids at baseline. The posterior mean (90% Bayesian credible intervals) 1y-OS with nivolumab was 54.35% (42.27–66.21), and the observed posterior probability of exceeding the 1y-OS of bevacizumab (34.5%, JO22506) was 99.7%. The median (90% confidence interval) overall and progression-free survival (PFS) was 13.09 months (10.38, 17.68) and 1.45 months (1.41, 1.54), respectively. One partial response was observed (objective response rate [ORR] 1/26 evaluable patients [3.8%]). The grade 3–5 treatment-related adverse event rate was 16.0%; most adverse events resolved and were manageable. CONCLUSION The 1y-OS with nivolumab monotherapy in Japanese patients was higher than that in the bevacizumab group in the JO22506 study. However, PFS and ORR were not improved compared with JO22506. The safety profile of nivolumab was consistent with that observed in other tumor types.
Efficacy of Ibrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Four Phase III Randomized Controlled Trials
Authors: Anita Sultan, Chandler Graf, Donald P. Quick, Sriman Swarup, Jonathan Kopel, Thura Win Htut, Nimesh Adhikari, Myat Min Han, Yin Mon Myat, Sanjay Awasthi, Lukman Tijani, Nicholas D'Cunha, Kyaw Zin Thein
Journal: Blood (2019)
Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas
Authors: Luis Colomo, Ivonne Vazquez, Natalia Papaleo, Marta Salido, Anna Puiggros, Blanca Espinet, Maria Rodriguez-Rivera, Ramon Diez-Feijoo, Blanca Sanchez-Gonzalez, Antonio Salar, Ana Ferrer, Leonor Arenillas, Marcio Andrade Campos, Xavier Calvo
Journal: Blood (2019)
The role of mechanotransduction versus hypoxia during simulated orthodontic compressive strain—an in vitro study of human periodontal ligament fibroblasts
Authors: Niklas Ullrich, Agnes Schröder, Jonathan Jantsch, Gerrit Spanier, Peter Proff, Christian Kirschneck
Journal: International Journal of Oral Science (2019)

During orthodontic tooth movement (OTM) mechanical forces trigger pseudo-inflammatory, osteoclastogenic and remodelling processes in the periodontal ligament (PDL) that are mediated by PDL fibroblasts via the expression of various signalling molecules. Thus far, it is unknown whether these processes are mainly induced by mechanical cellular deformation (mechanotransduction) or by concomitant hypoxic conditions via the compression of periodontal blood vessels. Human primary PDL fibroblasts were randomly seeded in conventional six-well cell culture plates with O2-impermeable polystyrene membranes and in special plates with gas-permeable membranes (Lumox®, Sarstedt), enabling the experimental separation of mechanotransducive and hypoxic effects that occur concomitantly during OTM. To simulate physiological orthodontic compressive forces, PDL fibroblasts were stimulated mechanically at 2 g·cm-2 for 48 h after 24 h of pre-incubation. We quantified the cell viability by MTT assay, gene expression by quantitative real-time polymerase chain reaction (RT-qPCR) and protein expression by western blot/enzyme-linked immunosorbent assays (ELISA). In addition, PDL-fibroblast-mediated osteoclastogenesis (TRAP+ cells) was measured in a 72-h coculture with RAW264.7 cells. The expression of HIF-1α, COX-2, PGE2, VEGF, COL1A2, collagen and ALPL, and the RANKL/OPG ratios at the mRNA/protein levels during PDL-fibroblast-mediated osteoclastogenesis were significantly elevated by mechanical loading irrespective of the oxygen supply, whereas hypoxic conditions had no significant additional effects. The cellular-molecular mediation of OTM by PDL fibroblasts via the expression of various signalling molecules is expected to be predominantly controlled by the application of force (mechanotransduction), whereas hypoxic effects seem to play only a minor role. In the context of OTM, the hypoxic marker HIF-1α does not appear to be primarily stabilized by a reduced O2 supply but is rather stabilised mechanically.
Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma
Authors: Xiang Li, Rachel Kositsky, Anupama Reddy, Cassandra Love, Kikkeri Naresh, Jean L. Koff, Ilja Nystrand, Sirpa Leppä, Annika Pasanen, Marja-Liisa Karjalainen-Lindsberg, Johannes Dunkel, Panu Kovanen, Qiu Qin, Govind Bhagat, Rebecca J Leeman-Neill, Rashmi S. Goswami, Sarah Wildeman, Jan Delabie, Richard Burack, Andrew G Evans, Catalina Amador, Ji Yuan, Hina Naushad Qureishi, Shaoying Li, Jie Xu, C. Cameron Yin, Anne Ortved Gang, Peter H. Norgaard, Mette Ø Pedersen, Jason Yongsheng Chan, Daryl Ming Zhe Cheah, Shin Yeu Ong, Chee Leong Cheng, Lianne Lee, Felik Paulua, Sarah L. Ondrejka, Eric D. Hsi, Magdalena Czader, Lin Wang, Amber Landis, Michael C. Churnetski, David L. Jaye, Christopher R. Flowers, Chad M. McCall, Jadee Neff, Matthew S. McKinney, Yuri Fedoriw, Eric Powers, Nathan D Montgomery, Agata M. Bogusz, Andrea Stafford Hintz, Alexandra E. Kovach, Nishitha Reddy, Mary Ann Thompson Arildsen, Emily F Mason, Ridas Juskevicius, William Choi, Rex Au-Yeung, Eric Tse, Vincent Sarno, Amy Chadburn, Rafael Lopez, Jennifer R Chapman, Amir Behdad, Neta Goldschmidt, John Goodlad, Cathy Burton, Raju Pillai, Abner Louissaint, Dina Sameh Soliman, Razvan Panea, Tushar Dave, Barbara Xiong, Eileen Smith, Sandeep Dave
Journal: Blood (2019)
Nlrp3 Inflammasome Activation in Bone Marrow-Residing Innate Immunity Cells Governs Circadian Changes in the Number of Circulating Hematopoietic Stem/Progenitor Cells in Peripheral Blood
Authors: Mateusz Adamiak, Andrzej Ciechanowicz, Monika Cymer, Marta Skoda, Mariusz Z Ratajczak
Journal: Blood (2019)